Dr. Daniel Von Hoff, MD, F.A.C.P. Joins Kinex team as the Chair of the Clinical Advisory Committee

BUFFALO, N.Y., Oct. 15, 2013 /PRNewswire/ -- Kinex Pharmaceuticals, a leading specialty biotech focused on the development and commercialization of next generation oral therapies for cancer and immunomodulatory diseases is pleased to welcome Dr. Daniel Von Hoff, MD, F.A.C.P., as Chair of its Clinical Advisory Committee.

Dr. Von Hoff is highly regarded as a medical oncologist and drug developer by his colleagues worldwide.  As the current Physician-in-Chief at the Translational Genomics Research Institute (TGen), and Professor of Medicine at the Mayo Clinic, Dr. Von Hoff and his team are focused on the development of new anticancer agents and the development of new treatments for patients with pancreatic cancer.  Further, he is the Chief Scientific Officer for US Oncology as well as for Scottsdale Healthcare's Clinical Research Institute.  Dr. Von Hoff has been the founder and/or editor of numerous scientific publications including Molecular Cancer Therapeutics and Clinical Cancer Research.  He was also a founder of ILEX ^TM Oncology; the company that had two anti-cancer agents approved by the FDA, Campath and Clolar. The company was sold to Genzyme.  In addition, he has been on both the AACR and American Society of Clinical Oncology Board of Directors, is a past president of the American Association for Cancer Research, is a fellow of the American College of Physicians and was a member of President Bush's National Cancer Advisory Board from 2004 to 2010.

Dr. Rudolf Kwan, Chief Medical Officer of Kinex Pharmaceuticals said, "Dan's remarkable breadth of experience will be a great resource for Kinex.  His contributions to the clinical investigation successes of paclitaxel, docetaxel, irinotecan, and nab-paclitaxel will prove invaluable to a number of our existing and planned clinical efforts, including Oraxol and Oratecan.  Further, his current work with new anticancer agents will help Kinex explore additional potential opportunities for KX01 and to further optimize our KX02 program."

"Dr. Von Hoff has been the recipient of many prestigious awards, has published and lectured very extensively, and has provided guidance and inspiration to many clinicians and scientists seeking to develop better cancer treatments," stated Dr. David Hangauer, Chief Scientific Officer of Kinex.  "However, these accolades pale in comparison to his dedication to cancer patients, and the advancement of compounds to that can improve their lives.  I am very much looking forward to working with Dan in the development of Kinex's compounds for cancer patients. Kinex now has 3 compounds allowed in the clinic by the US FDA and Dr. Von Hoff's expertise will be instrumental in guiding our development of these compounds in the clinic."

About Kinex:

Founded in 2004, Kinex is led by a strong, experienced Management Team and Board of Directors with a track record of achieving value-creating milestones and cumulative experience of over 250 years in both the pharmaceutical and biotechnology industries. This includes the filing of more than 11 NDAs and 20 INDs with the Food and Drug Administration and the development of more than 10 marketed products, including a number of blockbusters. Kinex has utilized the proprietary platform technologies Mimetica™, Opal™, and Orascovery™ to discover new compounds and to build a pipeline of drug candidates with unique mechanisms that address unmet medical needs with large market potential. With offices in both Buffalo, NY and Hong Kong, Kinex has numerous existing partnerships in Asia and New Zealand, as well as investors throughout the United States and Asia.

For Kinex inquiries please contact:

Dr. David Hangauer
Kinex Pharmaceuticals
701 Ellicott Street
Buffalo, NY 14203
[email protected]
716-898-8626

SOURCE Kinex Pharmaceuticals